To determine the relative risk of severe intraventricular hemorrhage (IVH) between two very early indomethacin treatment strategies.
INTRODUCTION
Prophylactic indomethacin (pINDO) has been shown to reduce the incidence of grades III to IV intraventricular hemorrhage (IVH) when compared to placebo. [1] [2] [3] [4] Patent ductus arteriosus (PDA) has been associated with an increased risk of IVH 5 and with alterations in cerebral blood flow. 6 Although indomethacin prophylaxis reduces the incidence of PDA when compared to placebo, [2] [3] [4] closure of the symptomatic PDA does not account statistically for the reduced risk of grades III to IV IVH. 2 The mechanism by which indomethacin protects against severe IVH remains uncertain, but has been attributed 7 instead to the drug's ability to both modulate cerebral blood flow 8 and induce cerebrovascular maturation. 9 This led to the suggestion that indomethacin be given prophylactically and not limited to infants with a symptomatic PDA.
Many neonatologists remain concerned about the universal administration of indomethacin to very low birth-weight (VLBW) infants. However, no study to date has compared risk of IVH when indomethacin is given very early as prophylaxis vs when it is given very early to close an open ductus arteriosus. Currently in our institution, many VLBW infants receive indomethacin before 36 hours of life. These infants are treated at similar frequencies with low-dose pINDO or with early treatment dose indomethacin for an asymptomatic but echocardiographically patent ductus arteriosus (EchoPDA). Thus, we were afforded the opportunity to evaluate the cerebroprotective effect of two different early indomethacin treatment strategies. pINDO and EchoPDA treatment differ as follows: (1) all infants receiving indomethacin prophylaxis are treated, whereas only those with an open ductus arteriosus are treated under the alternative strategy, (2) administration of pINDO is not dependent upon the availability of echocardiography, whereas EchoPDA evaluation may be delayed until daylight hours, and (3) the dose of pINDO is lower, but the interval between doses longer, allowing for an extended therapeutic window. Thus, we hypothesized that pINDO would be associated with a lower incidence of severe IVH than would the strategy to treat only after echocardiographic confirmation of ductus arteriosus patency.
METHODS
This study was approved by the Institutional Review Board of Magee-Womens Hospital.
Retrospective medical record review was conducted for infants born between July 1, 1997 and June 30, 2000 at <29 weeks gestation and <1350 g birth weight who were admitted to the neonatal intensive care unit at Magee-Women's Hospital (Pittsburgh, PA) within 12 hours of birth, survived for at least 24 hours, and had at least one cranial ultrasound performed. Infants were included if (a) they received prophylactic low-dose indomethacin or (b) they were evaluated for a PDA by an echocardiogram performed before 36 hours of life. Exclusion criteria included congenital anomalies of the brain, heart, or kidneys; hydrops fetalis; and twin-to-twin transfusion sequence.
Indomethacin strategy was assigned based on the drug dose and dosing schedule, use of the echocardiogram, and the attending physician's stated intent. Standard prophylactic low-dose indomethacin treatment was defined as the administration of 0.1 mg/kg of indomethacin beginning within 24 hours of birth and given every 24 hours for a total of three doses without prior echocardiographic confirmation of ductus arteriosus patency. The EchoPDA strategy was assigned to all infants who had echocardiographic evaluation for a PDA before 36 hours of life, whether or not a PDA was detected and indomethacin given. Treatment of the EchoPDA was defined as the administration of standard dose indomethacin (0.2 mg/kg, followed by 0.1 to 0.2 mg/ kg q12hour Â 2), beginning within 36 hours of birth. Infants in both treatment groups who received indomethacin were classified into one of four age categories based on their age at first dose: <6, 6 to 12, 12 to 24, and 24 to 36 hours. Infants whose doses or schedules were changed during therapy were analyzed with their initial assigned groups.
IVH was graded as by Papile et al., 10 with the most severe grade for each infant used in analysis. In general, routine cranial ultrasounds were obtained on day of life 14. Occasional earlier ultrasounds were obtained based on the clinical judgment of the attending physician. Follow-up scans were obtained if IVH or white matter injury was present on the initial scan.
Demographic variables, delivery room resuscitation and data regarding adverse events were collected from the infants' medical records. Adverse events were defined as serum creatinine >1.5 mg/ dl, urine output <1 cm 3 /kg/hour, necrotizing enterocolitis (Bell Stages II to IV 11 ), isolated ileal perforation, bronchopulmonary dysplasia (oxygen requirement at 28 days), cystic periventricular leukomalacia, and symptomatic PDA requiring subsequent medical and/or surgical treatment. Maternal charts were reviewed for number of doses of antenatal steroid administered, maternal risk factors for preterm delivery, and placental histopathology.
Statistical Analysis
The baseline rate of grades III to IV IVH for infants born at MageeWomens Hospital for the 2 years before this review (1995 to 1996) was 15%. We considered that a decrease in the rate of IVH from 15 to 5% would be clinically significant, and calculated that a sample size of 300 infants was needed to detect this difference with 80% power and an a error of 0.05.
The Kolmogorov-Smirnov Normality test confirmed that both birth weight and gestational age data had a non-normal distribution within each indomethacin treatment category. Therefore, the nonparametric Mann-Whitney U test was used to compare these variables between indomethacin groups. The Mann-Whitney test was also used to analyze the effect of age at first indomethacin dose on outcomes. w-square analysis or Fisher's exact test was used to determine if the frequencies of IVH and side effects differed between infants receiving the two indomethacin treatment. Binary logistic regression was used to determine the relative contributions of confounding factors on the incidence of IVH. Clinical variables previously shown to correlate with an increased risk of IVH 12 were tested by univariate modeling. Subsequently, variables that were significant in the univariate model were put into the multiple logistic regression model. Statistical analysis was done using Minitab for Windows, Release 12.23 (Minitab, State College, PA) and STATA 6.0 (Stata, College Station, TX).
RESULTS
Three hundred and one infants met gestational age and birthweight criteria. Of infants for whom complete clinical data were available, 102 received pINDO and 158 were evaluated by echocardiography. Of the latter, 136 (86%) had a PDA with left-toright shunting, 8 (5%) had a PDA with bidirectional shunting, and 14 (9%) had no PDA. Early indomethacin was given to 117 out of 158 (74%) infants with EchoPDA.
Nonstandard indomethacin dosing was administered to 21 infants (8%). Of infants given non-standard prophylactic dosing, eight received pINDO an initial dose of 0.2 mg/kg (followed by 0.1 mg/kg every 24 hours), two were dosed every 12 hours, and three were given both the higher initial dose and the every 12 hour schedule. In addition, four infants receiving pINDO had doses held for the following reasons: hyperkalemia (n ¼ 1), decreased urine output (n ¼ 2), and ''too healthy'' (n ¼ 1). Of infants treated for an EchoPDA, one was given an initial dose of 0.1 mg/kg and eight were dosed every 24 hours. Neonatologist progress notes for three of these infants stated that every 24 hours dosing was chosen because of impaired renal function.
Infants who received pINDO were younger than infants evaluated first for EchoPDA (Table 1) . Birth weight, gender, race, antenatal glucocorticoid administration, mode of delivery, Apgar scores, need for resuscitation, and percent outborn deliveries did not differ between groups (Table 1 ). The incidences of prenatal risk factors, including preterm labor and/or premature rupture of the fetal membranes (78 vs 81%), pre-eclampsia (17 vs 18%), and abruption (18 vs 13%) did not differ between infants who received pINDO and those treated under the EchoPDA strategy. Clinical
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Very Early Indomethacin Strategies and Intraventricular Hemorrhage signs of chorioamnionitis were less common in mothers of infants treated with pINDO (14 vs 26%, p ¼ 0.018), whereas placental evidence of chorioamnionitis (37 vs 46%) did not differ. IVH of grades III to IV was observed less frequently among infants who received pINDO than among infants in the EchoPDA group (Table 2, 6 vs 14%, p ¼ 0.041). IVH of grades I to II did not differ between treatment groups. The first dose of pINDO was administered earlier than the first dose of early treatment indomethacin (median 5 vs 18 hours, p<0.001). However, lower age at first indomethacin dose was not associated with a reduced risk of severe IVH.
Eighteen of the 260 infants were outborn. Grade III to IV IVH occurred more often among outborn than inborn infants (6/18 vs 22/242, p ¼ 0.001). Although the nine outborn infants who received pINDO were younger than the nine outborn infants treated under the EchoPDA strategy (median (range) ¼ 25.2 (23 to 28) vs 26.6 (24 to 28) weeks gestation, p ¼ 0.036), grades III to IV IVH occurred less often among outborn infants treated with pINDO (1/9 vs 5/9, p ¼ 0.046).
In univariate binary logistic regression, the following factors were associated with an increased risk of grades III to IV IVH: gestational age ( p ¼ 0.015), the number of doses of antenatal steroid received ( p ¼ 0.014), CPR at delivery ( p ¼ 0.000), volume resuscitation in the first 6 hours of life ( p ¼ 0.013), outborn delivery ( p ¼ 0.003), and indomethacin treatment strategy ( p ¼ 0.047). Mode of delivery, delivery room intubation, presence of respiratory distress syndrome, and receipt of any antenatal steroid were not significant. Multivariate analysis was then conducted using all the significant variables from the univariate analyses. The need for CPR and the indomethacin strategy were the only variables associated with severe IVH. Cardiac resuscitation was associated with an increased risk (OR 3.79, 95% CI 1.39 to 10.34, p ¼ 0.009) and pINDO was associated with a decreased risk (OR 0.27, 95% CI 0.10 to 0.77, p ¼ 0.014) of grades III to IV IVH. There were no differences in the rates of renal dysfunction, necrotizing enterocolitis, isolated ileal perforation, bronchopulmonary dysplasia, or periventricular leukomalacia between infants receiving pINDO and those treated under the EchoPDA strategy (Table 3 ). The incidence of subsequent symptomatic PDA necessitating repeated courses of indomethacin (14 (14%) vs 12 (8%)) or surgical ligation (4 (4%) vs 3 (2%)) did not differ between infants treated with pINDO and the EchoPDA strategy, respectively. There was no difference in the age at which indomethacin was first administered between infants with and without any of the adverse events, recurrent PDA, or surgical PDA ligation.
DISCUSSION
In this study, we evaluated the effect of two different early indomethacin treatment regimens on the risk of IVH among VLBW infants <29 weeks gestation and <1350 g birth weight. We found that the use of low-dose pINDO was associated with a reduction in grades III to IV IVH and no difference in side effects when compared to early treatment of the EchoPDA.
Low-dose pINDO had been shown previously to reduce the incidence of both PDA and grades III to IV IVH when compared to placebo. [1] [2] [3] In meta-analysis, 3 pINDO was not associated with a significant increase in renal dysfunction, necrotizing enterocolitis, abnormal bleeding, retinopathy of prematurity, or adverse neurodevelopmental outcome. Our findings extend these observations by demonstrating that pINDO has a beneficial effect against severe IVH and no difference in side effects when compared to an alternative early indomethacin treatment strategy.
In contemporary clinical practice, neonatologists may administer indomethacin in the first few days of life to close an asymptomatic but echocardiographically evident PDA in order to avoid PDA-related complications such as pulmonary hemorrhage. Such a regimen was adopted at our institution in 1989 as part of the Exosurf TM clinical trial, and became routine for any extremely low birth weight infant receiving surfactant therapy between the years of 1991 and 1997. In 1997, low-dose pINDO was introduced as a therapeutic alternative for ventilated VLBW infants. Over the years included in this retrospective review, VLBW infants considered for indomethacin treatment before 36 hours of life were treated at similar frequencies with pINDO or with early indomethacin treatment of the EchoPDA. Although most attending neonatologists at our center have a preferred indomethacin strategy, all employed both strategies over this time period, making it unlikely that physician-dependent management styles substantially affected our results.
Indomethacin prophylaxis has been shown to successfully close the ductus arteriosus and reduce the need for surgical ligation when compared to placebo. 2, 4 However, in at least one multicenter study, the protection afforded against IVH was not statistically related to the closure of the symptomatic PDA. 2 If the mechanism by which indomethacin reduces the risk of grades III to IV IVH was indeed related to the earlier closure of the ductus arteriosus, then we would have expected to find a protective effect among the infants in our cohort who received the drug early in life in order to close the asymptomatic, EchoPDA.
The ability of indomethacin to prevent IVH is likely multifactorial, and results in part from the ability of indomethacin to modulate the vasoreactivity and the structural integrity of the cerebral vasculature. Although indomethacin reduces baseline cerebral blood flow transiently, it also decreases the cerebral hyperemia that accompanies hypoxia/hypercapnia. 8 Indomethacin improves autoregulation in ventilated preterm lambs. 13 When indomethacin is given to piglets before the onset of hypotension, it does not prevent appropriate vasodilator responses, whereas the same dose given after the onset of hypotension may prevent cerebrovascular compensation, 14 suggesting that the earlier administration of the drug may in fact protect against cerebral ischemia. Indomethacin has been shown to induce deposition of germinal matrix basement membrane 9 and to reduce ischemiainduced alterations in the blood-brain barrier permeability. 15 In addition, indomethacin reduces the postasphyxial production of superoxide anions, 16 reducing the risk of reperfusion injury. Thus, indomethacin may reduce the swings in cerebral blood flow that have been implicated in the pathogenesis of IVH, make the germinal matrix more likely to withstand such pressure fluctuations without rupture, and protect against asphyxial injury.
The dose of indomethacin necessary to achieve the cerebrovascular effects has not been studied in premature humans. It is possible that the 0.1 mg/kg pINDO dose is sufficient for this effect. Furthermore, since indomethacin has a prolonged half-life in newborn VLBW infants, 17 the every 24-hour dosing schedule of pINDO extends the therapeutic window for up to 72 hours, as compared to the 48-hour window afforded by the every 12-hour dosing strategy used to treat the PDA.
Given the described cerebrovascular effects of indomethacin, we expected to find that earlier drug administration under either strategy would be associated with a reduced risk of severe IVH. To the contrary, we did not find such a relation. The absence of a We found no difference in rates of renal dysfunction, necrotizing enterocolitis, and isolated ileal perforation among infants treated with either of the two early treatment regimens. Although our study may have lacked sufficient power to test whether one strategy is safer than the other, our data are consistent with that of the Cochrane meta-analysis, 3 which demonstrated that pINDO is not associated with increased side effects when compared to placebo. We postulate that indomethacin-related side effects are seen primarily in older infants treated for symptomatic PDA, in whom baseline abnormalities of organ perfusion exist. For example, it has been shown that a symptomatic PDA reduces baseline blood flow velocity in the superior mesenteric 18 and the middle cerebral 19 arteries. Indomethacin treatment of the symptomatic PDA reduces mesenteric blood flow velocity by an additional 40 20 to 50%, 18 and reduces middle cerebral artery blood flow velocity by an additional 40 20 to 75%. 21 We have shown previously that the reduction in mean mesenteric blood flow velocity following administration of pINDO is substantially less F only 15%, 22 making gut hypoxia less likely. Similarly, the reduction in middle cerebral artery blood flow velocity after pINDO is only 27%. 22 Since white matter injury was not detected at higher rates among infants who received pINDO as compared to placebo, 3, 4, 23 it remains probable that the modest reductions in cerebral blood flow velocity following pINDO 22 are insufficient to result in hypoxic-ischemic injury to the premature brain.
Neurodevelopmental outcome data obtained at 3-4 , 36-23 and 54-7 months of age from VLBW infants treated in large randomized controlled trials of indomethacin prophylaxis confirm that indomethacin prophylaxis safely reduces the incidence of grades III to IV IVH and PDA without significant side effects or adverse effects on long-term neurodevelopmental outcome. Although indomethacin prophylaxis reduced the incidence of severe IVH, it did not reduce the incidence of cerebral palsy 3, 4, 7, 23 and it was associated with only subtle improvements in cognitive outcome, specifically in the area of language development. 7 VLBW infants remain at high risk of adverse neurodevelopmental outcome whether or not they receive indomethacin prophylaxis. However, since there is a cost associated with echocardiography, since echocardiography is not always immediately available, and since pINDO reduces the incidence both of severe IVH and of symptomatic PDA, it may be both more clinically effective and cost effective 24 to use indomethacin prophylactically. In conclusion, we found that pINDO reduced severe IVH when compared to a strategy of early echocardiography followed by indomethacin treatment only if the ductus arteriosus was patent. pINDO should be considered a practical alternative for nurseries that employ any very early indomethacin strategy.
